Clinical Trials · NCT01424241

Effects of Sandostatin LAR® in Acromegaly

CompletedPhase 4Octreotide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Columbia University
Enrollment
21
Start date
Oct 2006
Locations
1 site, United States
Primary endpoint
IGF-1 Level on Sandostatin LAR
View Octreotide compound reference